Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
INCB086550 · 1 trial · 1 indication
Defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug.
| Arm | Type | Description |
|---|---|---|
| INCB086550 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| INCB086550 | DRUG | INCB086550 will be orally administered once or twice daily in continuous or intermittent dose schedules. |
Inclusion Criteria: * Histologically confirmed advanced solid tumors with measurable lesions per RECIST v1.1 or RANO for primary brain tumors that are considered nonamenable to surgery or other curative treatments or procedures. Tumor lesions located in a previously irradiated area, or in an area s...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
INCB086550 is an investigational small molecule being studied for the treatment of advanced solid tumors. It is being developed by Incyte Corporation and has been evaluated in a Phase 1 clinical trial in adult patients with solid tumors. It is not approved for any indication.
INCB086550 targets CD274, also known as PD-L1. It is an inhibitor of this target. By inhibiting CD274, INCB086550 is designed to interfere with a pathway that tumors use to evade immune detection, which is the rationale for its study in solid tumors.
INCB086550 is being developed by Incyte Corporation, which trades on the Nasdaq under the ticker INCY. Incyte is the sponsor of the clinical trial evaluating INCB086550 in patients with advanced solid tumors.
INCB086550 is in Phase 1 clinical development. It has completed a Phase 1 trial in advanced solid tumors. The drug remains investigational and has not been approved by the FDA or any regulatory authority for commercial use.
INCB086550 has been studied in one clinical trial: NCT03762447, titled A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors. This Phase 1 trial is completed and enrolled 138 participants across the United States, Belgium, France, Italy, and the United Kingdom.